Among them, compound (R)-23a demonstrates significant DNMT1 and HDAC inhibition both in vivo and in cells (colorectal tumor) and largely phenocopied the synergistic effects of combined DNMT1i and HDACi in reactivating epigenetically silenced tumor suppressor genes (TSGs).744 Huang et al. designed a dual DNMT and HDAC inhibitor (termed DNMT/HDACi) 15a, which exhibits immunomodulatory functions by increasing the intracellular level of double-stranded RNA to activate the RIG-I/MAVS pathway and enhances the effectiveness of immune checkpoint blockade therapy.743. The gene discussed is HDAC9; the disease is colorectal neoplasm.